Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Non Operating Investment Income (2022 - 2024)

Indivior Pharmaceuticals has reported Non Operating Investment Income over the past 3 years, most recently at $3.0 million for Q4 2024.

  • For Q4 2024, Non Operating Investment Income changed N/A year-over-year to $3.0 million; the TTM value through Dec 2024 reached $3.0 million, changed N/A, while the annual FY2024 figure was $9.0 million, N/A changed from the prior year.
  • Non Operating Investment Income for Q4 2024 was $3.0 million at Indivior Pharmaceuticals, up from -$1.0 million in the prior quarter.
  • Over five years, Non Operating Investment Income peaked at $3.0 million in Q4 2024 and troughed at -$1.0 million in Q1 2023.
  • A 3-year average of $1.0 million and a median of $1.0 million in 2022 define the central range for Non Operating Investment Income.